No distinct dose adjustment recommended when tofacitinib coadministered with strong CYP2C19 inhibitors; lessen tofacitinib dose if coadministered with the two moderate CYP3A4 and strong CYP2C19 inhibitors .To view formulary details to start with develop a listing of plans. Your checklist will be saved and can be edited Anytime.For sentralt godkjent

Article Under Review